DELAYED INNOVATION
Why are overall timelines moving in the wrong direction?

The most recent Time and Cost to Market report from AgbioInvestor
indicates the following significant trends:

13.1

16.5

20122022

years

TIME-TO-MARKET
HAS GONE UP
The mean time tobring a new GM trait
to commercialisation
has increased 26%
since 2012.

years

$136
million2012 2022

Delivering a new GM trait to market
requires an average investment of:

16.5 8.5
YEARS

More than half that time –years – is spent on
regulatory approval alone.
AND$115MILLION

$115

million

COST-TO-MARKETHAS COME DOWN
Overall costs havefallen by $21M, driven
primarily by greater
efficiency in the trait
discovery phase.

WHAT’S TAKING SO LONG?
53.2

The regulatory phasemonthsaccounts for 37.6% of

the total cost – but takes
up 51.1% of the time.

The regulatory phaseaccounts for 37.6% of
total costs.

204.6
months142.5

Discovery (Early, Late)monthsGenetic Event Construction and Testing
Regulatory

HOW DO WE FIX IT?
In nearly all other markets, as regulators become
more familiar with a technology, the time to approval
decreases. This trend is reversed for GM crops inmost jurisdictions.

UNDER DEVELOPER CONTROLTechnology developers have improvedand become more efficient in thediscovery and optimization phases.

A MORE HARMONIZED GLOBAL REGULATORYFRAMEWORK WOULD:

Improve time to market
Promote innovation
And ultimately help growers andconsumers alike
Source: AgbioInvestor 2022/CropLife International Members
Survey conducted by AgbioInvestor and reflects the input of four global brands for the period 2017–2022.
Previous study results are from a similar survey conducted for the period 2008–2012.

BEYOND DEVELOPER CONTROLThe regulatory phase has increased intime by 140% since the 2008-2012 study.

DELAYED INNOVATION
Why are overall timelines moving in the wrong direction?

INCREASING REGULATORY TIMELINES

Patent LifetimeYears

1Development Stages

2345678910111213

14

15

16

Activity Stages

Product LaunchConstruct Optimization
Commercial Event Production and Selection

Genetic EventConstruction
and Testing

Introgression, Breeding,and Wide-Area Testing
Regulatory ScienceRegulatory

18192021222324

25

Commercial Sales

Early Discovery
Late Discovery

Discovery

17R&D Phases

The time to market has increased
from 13.1 years (2008-2012) to16.5 years (2017-2022).

Registration and Regulatory Affairs

TOTAL COSTS ATTRIBUTED TO EACH DEVELOPMENT CATEGORY$35.1Mthe total time (86 months), the$43.2M$136
milliontotal

Discovery (Early, Late)

timeframe is now almost 1.5x longer.

$115

milliontotal$69.9M

2008-2012

regulatory required 36.7% of$7.6M$31.0M

Compared to 2012, when

$64.2Man additional 40 MONTHS

2017-2022
Genetic Event Constructionand Testing

Slow regulatory approvals result inRegulatoryof lost commercial revenuefor product developers.

Compared to 2012, time spent in discovery

Time spent in construction and testinghas decreased from 23% to 13.3%.

has dropped from 40.2% to 35.6%.

It’s clear that innovation is needed to achieve zero hunger, improve foodsecurity, and adapt to and mitigate climate change. Developers have tools andresources that can ease the burden on the world’s farmers and help them farmsustainably and productively, but those in the food value chain must haveaccess to these innovations in a timely manner. Global challenges like foodsecurity and climate change depend on it.

Source: AgbioInvestor 2022/CropLife International Members
Survey conducted by AgbioInvestor and reflects the input of four global brands for the period 2017–2022.
Previous study results are from a similar survey conducted for the period 2008–2012.